Role of Sex Hormone-Binding Globulin (SHBG) in Females
SHBG is a liver-produced glycoprotein that regulates the bioavailability of sex steroids by binding testosterone and estradiol with high affinity, thereby controlling free hormone levels and modulating their biological effects across multiple organ systems in women.
Primary Physiological Functions
Regulation of Sex Steroid Bioavailability
SHBG serves as the principal determinant of free (bioactive) testosterone and estradiol in circulation 1. The protein binds sex steroids with high affinity and specificity, creating three distinct fractions in plasma:
- SHBG-bound (biologically inactive in most tissues)
- Albumin-bound (weakly bound, potentially bioavailable)
- Free hormone (immediately bioavailable)
Only the free and albumin-bound fractions can enter target cells and exert biological effects 1. In women with androgen excess (such as hirsutism), low SHBG levels result in elevated free testosterone despite normal total testosterone, making free testosterone measurement more sensitive for detecting hyperandrogenism 1.
Factors Regulating SHBG Levels in Women
SHBG synthesis is stimulated by estrogens and suppressed by multiple factors 1, 2:
Factors that INCREASE SHBG:
- Estrogen exposure
- Hyperthyroidism
- Aging (in some contexts)
- Hepatic disease (early stages)
Factors that DECREASE SHBG:
- Androgens
- Hyperinsulinemia and insulin resistance
- Obesity and increased body fat
- Hypothyroidism
- Polycystic ovary syndrome (PCOS)
The relationship between SHBG and body fat distribution is particularly important—SHBG levels decrease with increasing waist-to-hip ratio, especially in postmenopausal women 3.
Clinical Significance Across Reproductive Life
Premenopausal Women
In premenopausal women, SHBG levels are positively correlated with estradiol and negatively correlated with testosterone and insulin 3. Estradiol is a major determinant of SHBG concentrations in premenopausal women, with this relationship becoming less significant after menopause 3.
Women with PCOS characteristically have low SHBG levels due to hyperinsulinemia and hyperandrogenism, which increases bioavailable androgens and perpetuates the syndrome's pathophysiology 4, 5. Low SHBG in PCOS increases free testosterone, driving hirsutism, acne, and ovarian dysfunction 1, 4.
Menopausal Transition
Despite the marked reduction in estradiol levels at menopause, SHBG concentrations do not significantly differ between premenopausal and postmenopausal women 3. However, the determinants of SHBG change: in postmenopause, the relationship with estradiol weakens while the negative correlation with waist-to-hip ratio strengthens 3.
Testosterone levels decline modestly with age, but this decline is gradual and not specifically linked to menopause 6, 7. The free androgen index may actually increase in some postmenopausal women due to declining SHBG 7.
Advanced Liver Disease
In women with chronic liver disease, SHBG synthesis is initially stimulated by altered estrogen metabolism, but ultimately declines with progression to decompensated cirrhosis 2. This contributes to hormonal disruption, menstrual irregularities, and sexual dysfunction in women with advanced hepatic disease 2.
Direct Cellular Effects Beyond Transport
SHBG is not merely a passive carrier protein. Emerging evidence demonstrates that SHBG interacts directly with cell membrane receptors and can initiate intracellular signaling pathways 8, 9.
In breast tissue, SHBG cross-talks with estradiol-activated pathways and inhibits estradiol-induced breast cancer cell growth and proliferation 8. Higher plasma SHBG levels are associated with significantly reduced risk of estrogen receptor-positive breast cancer, particularly in postmenopausal women 10, 8.
Animal studies show that SHBG infused into specific brain regions increases female sexual receptivity, suggesting direct neuroendocrine effects independent of its steroid-binding function 9.
Clinical Applications and Diagnostic Utility
Androgen Excess Evaluation
When evaluating hirsutism or hyperandrogenism, measuring both total testosterone and SHBG allows calculation of free or bioavailable testosterone, which is more sensitive than total testosterone alone 1. Women with low SHBG may have elevated free testosterone despite normal total testosterone levels 1.
Metabolic and Cardiovascular Risk Assessment
Low SHBG is strongly associated with insulin resistance, metabolic syndrome, type 2 diabetes risk, and cardiovascular disease 4, 11, 12. In women with PCOS, low SHBG and elevated free androgen index correlate with increased cardiovascular risk factors 4.
SHBG may serve as an early biomarker for metabolic dysfunction and non-alcoholic fatty liver disease in women, particularly those with PCOS 5.
Hormonal Contraception Effects
Oral contraceptives increase SHBG production through their estrogen component, thereby reducing bioavailable androgens 4. The progestin in hormonal contraceptives suppresses ovarian androgen production while estrogen increases SHBG, creating a dual mechanism for reducing free testosterone 4.
Important Clinical Caveats
Accurate SHBG measurement requires standardized assays, as different laboratory methods use varying standards and yield discrepant results 1, 7. When calculating free testosterone from total testosterone and SHBG, the dissociation constant must be accurate and universally agreed upon 7.
SHBG levels vary with menstrual cycle phase in ovulating women, being highest at midcycle 6. For clinical reliability, multiple samples or appropriately timed samples with cycle-specific reference ranges should be obtained 6.
In women with epilepsy treated with enzyme-inducing antiepileptic drugs (carbamazepine, phenobarbital, phenytoin), SHBG production increases, reducing bioavailable sex hormones and potentially causing menstrual disturbances 13.